Cholesterol Metabolites as Markers for CYP3A Induction

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
CYP3A4 Induction
Interventions
DRUG

Rifampicin treatment

induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)

Trial Locations (1)

SE-14186

Clinical Pharmacology Trial Unit (CPTU), Karolinska University Hospital, Stockholm

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Karolinska University Hospital

OTHER